I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Long response duration to pembrolizumab in metastatic, cast..:
Tsukasa Yoshida
;
Hiroshi Yaegashi
;
Ren Toriumi
...
https://www.frontiersin.org/articles/10.3389/fonc.2022.912490/full. , 2022
Link:
https://doi.org/10.3389/fonc.2022.912490
RT Journal T1
Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:3617b534a7624effad2a34d14e318bda&Exemplar=1&LAN=DE A1 Tsukasa Yoshida A1 Hiroshi Yaegashi A1 Ren Toriumi A1 Suguru Kadomoto A1 Hiroaki Iwamoto A1 Kouji Izumi A1 Yoshifumi Kadono A1 Hiroko Ikeda A1 Atsushi Mizokami PB Frontiers Media S.A. YR 2022 K1 metastatic castration-resistant prostate cancer (mCRPC) K1 neuroendocrine differentiation (NED) K1 microsatellite instability-high (MSI-high) K1 immune checkpoint inhibitor (ICI) K1 pembrolizumab K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://www.frontiersin.org/articles/10.3389/fonc.2022.912490/full LK http://dx.doi.org/https://doi.org/10.3389/fonc.2022.912490 DO https://doi.org/10.3389/fonc.2022.912490 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)